Pediatric Infectious Diseases Unit, University Children's Hospital Mannheim, Heidelberg University, Germany.
Pediatr Infect Dis J. 2012 Aug;31(8):859-62. doi: 10.1097/INF.0b013e3182620e52.
Infant formulae and food products marketed for children have been increasingly supplemented with probiotics and/or prebiotics. A vast number of studies have accounted for the transit of probiotic use from alternative to more evidence-based medicine. Data support the use of certain probiotics for the adjunct treatment of acute viral gastroenteritis, and for prevention of gastrointestinal diseases. Further roles of prebiotics and probiotics are seen in the prevention of overall infectious diseases and respiratory infections. Data from well-conducted randomized-controlled trials support the therapeutic role for probiotics toward necrotizing enterocolitis in preterm infants. However, it is difficult to translate heterogeneous-based study results, which are mainly due to varying genera, strains, doses, study settings and measured outcomes, into evidence-based recommendations. This article focuses on the evidence of clinical benefits of prebiotics, probiotics and synbiotics toward prevention and treatment of pediatric infectious diseases.
婴儿配方食品和针对儿童的食品产品越来越多地添加了益生菌和/或益生元。大量研究表明,益生菌的使用已经从替代医学转向更基于证据的医学。数据支持某些益生菌用于辅助治疗急性病毒性胃肠炎,以及预防胃肠道疾病。益生元和益生菌在预防整体传染病和呼吸道感染方面具有进一步的作用。来自精心设计的随机对照试验的数据支持益生菌对早产儿坏死性小肠结肠炎的治疗作用。然而,将基于异质性的研究结果(主要是由于不同的属、菌株、剂量、研究环境和测量结果)转化为基于证据的建议是困难的。本文重点介绍了益生元、益生菌和合生菌在预防和治疗儿科传染病方面的临床益处证据。